A Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

NCT01546038 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

255

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: PF-04449913
DRUG: Low dose ARA-C (LDAC)
DRUG: PF-04449913
DRUG: Decitabine
DRUG: PF-04449913
DRUG: Daunorubicin
DRUG: Cytarabine
DRUG: PF-04449913
DRUG: Daunorubicin
DRUG: Cytarabine
DRUG: PF-04449913
DRUG: Low dose ARA-C (LDAC)

Sponsor

Pfizer